Eruptive basal cell carcinoma and lenalidomide: rising awareness among dermatologists
Lenalidomide (L) is approved for treating multiple myeloma (MM), being preferred to its parent drug, thalidomide, for its superior safety. We report the case of a patient developing more than 10 basal cell carcinomas (BCCs) within 1 month of starting L. Notably, his treating hematologist neither rec...
Guardat en:
| Autors principals: | , , |
|---|---|
| Format: | Llibre |
| Publicat: |
PAGEPress Publications,
2022-07-01T00:00:00Z.
|
| Matèries: | |
| Accés en línia: | Connect to this object online. |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|
Internet
Connect to this object online.3rd Floor Main Library
| Signatura: |
A1234.567 |
|---|---|
| Còpia 1 | Disponible |